Navigation Links
PROLOR Biotech's Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society
Date:9/27/2010

that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in PROLOR's filings with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.PROLOR CONTACT:

MEDIA CONTACT:Shai Novik, President

Barbara LindheimPROLOR Biotech, Inc.

GendeLLindheim BioCom PartnersTel: +1 866 644-7811

+1 212 918-4650Email: shai@prolor-biotech.com
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. PROLOR Biotech Awarded Two U.S. Patents for Its Longer-Acting Human Growth Hormone and Longer-Acting Erythropoietin
2. PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
3. PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug
4. PROLOR Biotech to Present at the UBS 2009 Global Life Sciences Conference
5. PROLOR Biotech Announces Initiation of Phase I Clinical Trial for its Long-Acting Growth Hormone
6. Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs
7. Modigene Awarded Second-Year Grant by Israeli Government to Support Development of Its Longer-Acting Human Growth Hormone
8. Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response
9. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
10. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
11. UC Riverside researcher develops novel method to grow human embryonic stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ... July 06, 2015 , ... ... potential to reveal how blood flows in the brain during stroke, providing information ... , A new article published in the journal Neurophotonics describes work ...
(Date:7/6/2015)... 6, 2015  Approximately 1% of the population inherits ... chromosomes. These individuals are three times more likely to ... one of the nation,s leading medical journals by researchers ... Photo - http://photos.prnewswire.com/prnh/20150706/230685 ... causes roseola (also known as "sixth disease") and occasional ...
(Date:7/6/2015)... 2015 Research and ... of the "Biotechnology for the Non-Biotechnologist" ... the Non-Biotechnologist, ideal for non-Scientists and Scientists needing ... potential of biotechnology. Ideal for Non-Scientists ... principles, techniques, and potential of biotechnology ...
(Date:7/6/2015)... , July 6, 2015 ImmunoCellular Therapeutics, ... of an agreement with Novella Clinical (Novella), ... in patients with newly diagnosed glioblastoma. Novella is a ... services to small to mid-sized oncology companies. The ICT-107 ... in the US, Europe and ...
Breaking Biology Technology:Reducing Stroke Damage May be Next Application for OCT Technology Now Widely Used in Eye and Vision Healthcare 2Reducing Stroke Damage May be Next Application for OCT Technology Now Widely Used in Eye and Vision Healthcare 3Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced today that ... for the brand name Ranexa(R) (ranolazine)., On July ... granted,marketing authorization for ranolazine in all 27 European Union ... approval for the Ranexa brand name in Europe provides,important ...
... Named as CEO ... COO, ALTAMONTE SPRINGS, Fla., Aug. 14 Milestone ... and commercialization of niche oncology products, today,announced the appointment ... 12, 2008. Current President, CEO and Co-founder, Frank,Jacobucci, will ...
... Bio-,Pharmaceutical Technology, Inc (OTC Bulletin Board: HFGB), a ... raw materials,for use in pharmaceutical, nutraceutical and food ... for the three and six month periods,ended June ... 2008, sales of our products increased,substantially. Revenue received ...
Cached Biology Technology:CV Therapeutics Receives European Approval for the Brand Name Ranexa(R) 2Milestone Biosciences, LLC Further Strengthens Executive Management Team 2Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008 2
(Date:7/7/2015)... , June 30, 2015 ... has announced the addition of the "Capacitive ... offering. To this date, fingerprint sensing ... technology and fingerprint sensors are well developed. This ... sensing technology. The domain of capacitive ...
(Date:7/7/2015)... 7, 2015  Based on its recent analysis ... recognizes Credence ID, LLC with the 2015 Asia-Pacific ... the Year Award. Credence ID has developed a ... mission of offering enrollment and identification solutions to ... ID was formed by experts from the mobile ...
(Date:7/7/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a ... a revised version of one of its first 30 second commercials ... in New York , Chicago ... Francisco metro areas.    , , , ... all the cards in your wallet and keep your identity secure. ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... University of Manchester researchers are ridding diabetic patients of ... with maggots. , Professor Andrew Boulton and his team ... patients whose foot ulcers were contaminated with MRSA and ... period of three weeks, much quicker than the 28-week ...
... the nation are protesting a new and narrowed definition ... Monday to U.S. Secretary of the Interior Dirk Kempthorne, ... the House Committee on Natural Resources, they warn that ... the Solicitor of the U.S. Department of the Interior ...
... nerves in the mammalian brain’s white matter do more than ... process information the way gray matter cells do. , The ... the March issue of Nature Neuroscience, shows that brain cells ... , “We were surprised to see these nerve axons ...
Cached Biology News:Maggots rid patients of MRSA 2Legal ruling may put endangered species in danger 2Brain's white matter -- More 'talkative' than once thought 2